🚀 VC round data is live in beta, check it out!
BGI Genomics Valuation Multiples
Discover revenue and EBITDA valuation multiples for BGI Genomics and similar public comparables like Genus, Dr. Lal PathLabs, Insight Lifetech, Tecan Group and more.
BGI Genomics Overview
About BGI Genomics
BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.
Founded
2010
HQ
Employees
N/A
Website
Financials (FY)
EV
$2B
BGI Genomics Financials
BGI Genomics reported last fiscal year revenue of $567M and negative EBITDA of ($2M).
In the same fiscal year, BGI Genomics generated $235M in gross profit, ($2M) in EBITDA losses, and had net loss of ($124M).
Revenue (LTM)
BGI Genomics P&L
In the most recent fiscal year, BGI Genomics reported revenue of $567M and EBITDA of ($2M).
BGI Genomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $567M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $235M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 41% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($2M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (0%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (11%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($124M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (22%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BGI Genomics Stock Performance
BGI Genomics has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
BGI Genomics' stock price is $5.85.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -1.3% | XXX | XXX | XXX | $-0.30 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBGI Genomics Valuation Multiples
BGI Genomics trades at 3.5x EV/Revenue multiple, and (1220.6x) EV/EBITDA.
EV / Revenue (LTM)
BGI Genomics Financial Valuation Multiples
As of April 18, 2026, BGI Genomics has market cap of $2B and EV of $2B.
Equity research analysts estimate BGI Genomics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BGI Genomics has a P/E ratio of (19.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1220.6x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (33.4x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 8.5x | XXX | XXX | XXX |
| P/E | — | XXX | (19.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (31.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BGI Genomics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BGI Genomics Margins & Growth Rates
BGI Genomics' revenue in the last fiscal year declined by (11%).
BGI Genomics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (11%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (0%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (154%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BGI Genomics Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics and Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BGI Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| Dr. Lal PathLabs | XXX | XXX | XXX | XXX | XXX | XXX |
| Insight Lifetech | XXX | XXX | XXX | XXX | XXX | XXX |
| Tecan Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Veracyte | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BGI Genomics M&A Activity
BGI Genomics acquired XXX companies to date.
Last acquisition by BGI Genomics was on XXXXXXXX, XXXXX. BGI Genomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BGI Genomics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBGI Genomics Investment Activity
BGI Genomics invested in XXX companies to date.
BGI Genomics made its latest investment on XXXXXXXX, XXXXX. BGI Genomics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BGI Genomics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BGI Genomics
| When was BGI Genomics founded? | BGI Genomics was founded in 2010. |
| Where is BGI Genomics headquartered? | BGI Genomics is headquartered in China. |
| Is BGI Genomics publicly listed? | Yes, BGI Genomics is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of BGI Genomics? | BGI Genomics trades under 300676 ticker. |
| When did BGI Genomics go public? | BGI Genomics went public in 2017. |
| Who are competitors of BGI Genomics? | BGI Genomics main competitors are Genus, Dr. Lal PathLabs, Insight Lifetech, Tecan Group. |
| What is the current market cap of BGI Genomics? | BGI Genomics' current market cap is $2B. |
| What is the current revenue of BGI Genomics? | BGI Genomics' last fiscal year revenue is $567M. |
| What is the current EV/Revenue multiple of BGI Genomics? | Current revenue multiple of BGI Genomics is 3.5x. |
| Is BGI Genomics profitable? | No, BGI Genomics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.